ExSeed Health develops a smartphone‑based at‑home sperm testing kit that provides a live video of the sample, quantitative analysis of sperm concentration and motility, and a fertility score on users' phones within minutes. The device is BSI‑approved and CE‑certified, delivering over 95% accuracy versus certified laboratory equipment. Results are paired with behavioural and diet data to generate a personalised 90‑day lifestyle intervention program, and the app offers access to fertility doctors, exportable reports, and clinic recommendations. ExSeed sells direct‑to‑consumer and partners with clinics and industry players, reporting more than 10,000 tests on its platform as of December 2021. Financially, the company has recorded more than 4x revenue growth since December 2020 and average month‑on‑month sales growth rates above 20% in 2021. The team operates in London and Copenhagen and works with partners including the European Sperm Bank and the University of Copenhagen. The company was founded in 2017 and is positioning the product for further European expansion and partnerships with healthcare providers including the NHS and private fertility clinics.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2022